(SNN) Smith & Nephew SNATS - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE (USA) | Market Cap: 12.989m USD | Total Return: 6.9% in 12m
Avg Turnover: 36.7M
EPS Trend: -9.4%
Qual. Beats: 0
Rev. Trend: 85.8%
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
Smith & Nephew (SNN) is a global medical technology company specializing in three primary segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The firm manufactures a diverse range of surgical implants, visualization technologies for minimally invasive procedures, and specialized treatments for chronic wounds and regenerative medicine. Founded in 1856, the company serves healthcare providers across international markets, focusing on joint replacement and soft tissue repair.
Operating within the Health Care Equipment sector, the company utilizes a business model driven by high research and development costs and strict regulatory compliance. This industry is characterized by high barriers to entry due to the technical complexity of surgical hardware and the necessity of long-term clinical data to secure market share. For deeper insights into these industry drivers, investors may wish to review the detailed metrics on ValueRay.
- Orthopaedics segment recovery hinges on elective surgery volume and surgical robotics adoption
- Sports Medicine revenue growth depends on global expansion of minimally invasive procedures
- Advanced Wound Management margins face pressure from raw material and logistics inflation
- Supply chain efficiency improvements are critical to meeting 2025 operating profit targets
- Regulatory approval timelines for new implant technologies impact long-term market share gains
| Net Income: 1.04b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 10.56 > 1.0 |
| NWC/Revenue: 20.92% < 20% (prev 32.03%; Δ -11.11% < -1%) |
| CFO/TA 0.22 > 3% & CFO 2.28b > Net Income 1.04b |
| Net Debt (2.99b) to EBITDA (2.82b): 1.06 < 3 |
| Current Ratio: 2.57 > 1.5 & < 3 |
| Outstanding Shares: last quarter (436.5m) vs 12m ago -50.03% < -2% |
| Gross Margin: 68.80% > 18% (prev 0.70%; Δ 6.81k% > 0.5%) |
| Asset Turnover: 114.2% > 50% (prev 79.40%; Δ 34.78% > 0%) |
| Interest Coverage Ratio: 5.05 > 6 (EBITDA TTM 2.82b / Interest Expense TTM 329.4m) |
| A: 0.24 (Total Current Assets 4.10b - Total Current Liabilities 1.59b) / Total Assets 10.5b |
| B: 0.51 (Retained Earnings 5.32b / Total Assets 10.5b) |
| C: 0.16 (EBIT TTM 1.66b / Avg Total Assets 10.5b) |
| D: 1.07 (Book Value of Equity 5.52b / Total Liabilities 5.17b) |
| Altman-Z'' = 5.42 = AAA |
| DSRI: 0.74 (Receivables 1.43b/1.35b, Revenue 12.0b/8.37b) |
| GMI: 1.02 (GM 68.80% / 70.20%) |
| AQI: 1.02 (AQ_t 0.45 / AQ_t-1 0.44) |
| SGI: 1.43 (Revenue 12.0b / 8.37b) |
| TATA: -0.12 (NI 1.04b - CFO 2.28b) / TA 10.5b) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of May 28, 2026, the stock is trading at USD 30.21 with a total of 1,188,638 shares traded.
Over the past week, the price has changed by -2.04%,
over one month by -5.86%,
over three months by -16.89% and
over the past year by +6.92%.
Smith & Nephew SNATS has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold SNN.
- StrongBuy: 1
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 35 | 15.8% |
P/E Trailing = 21.3497
P/E Forward = 13.947
P/S = 2.1072
P/B = 2.4558
P/EG = 1.2348
Revenue TTM = 12.0b USD
EBIT TTM = 1.66b USD
EBITDA TTM = 2.82b USD
Long Term Debt = 3.03b USD (from longTermDebt, last quarter)
Short Term Debt = 150.0m USD (from shortTermDebt, last quarter)
Debt = 3.54b USD (from shortLongTermDebtTotal, last quarter) + Leases 216.0m
Net Debt = 2.99b USD (calculated: Debt 3.54b - CCE 557.0m)
Enterprise Value = 16.0b USD (13.0b + Debt 3.54b - CCE 557.0m)
Interest Coverage Ratio = 5.05 (Ebit TTM 1.66b / Interest Expense TTM 329.4m)
EV/FCF = 10.94x (Enterprise Value 16.0b / FCF TTM 1.46b)
FCF Yield = 9.14% (FCF TTM 1.46b / Enterprise Value 16.0b)
FCF Margin = 12.18% (FCF TTM 1.46b / Revenue TTM 12.0b)
Net Margin = 8.66% (Net Income TTM 1.04b / Revenue TTM 12.0b)
Gross Margin = 68.80% ((Revenue TTM 12.0b - Cost of Revenue TTM 3.74b) / Revenue TTM)
Gross Margin QoQ = 65.56% (prev 70.62%)
Tobins Q-Ratio = 1.53 (Enterprise Value 16.0b / Total Assets 10.5b)
Interest Expense / Debt = 9.30% (Interest Expense 329.4m / Debt 3.54b)
Taxrate = 20.39% (84.7m / 415.6m)
NOPAT = 1.32b (EBIT 1.66b * (1 - 20.39%))
Current Ratio = 2.57 (Total Current Assets 4.10b / Total Current Liabilities 1.59b)
Debt / Equity = 0.67 (Debt 3.54b / totalStockholderEquity, last quarter 5.29b)
Debt / EBITDA = 1.06 (Net Debt 2.99b / EBITDA 2.82b)
Debt / FCF = 2.05 (Net Debt 2.99b / FCF TTM 1.46b)
Total Stockholder Equity = 5.32b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.89% (Net Income 1.04b / Total Assets 10.5b)
RoE = 19.51% (Net Income TTM 1.04b / Total Stockholder Equity 5.32b)
RoCE = 19.91% (EBIT 1.66b / Capital Employed (Equity 5.32b + L.T.Debt 3.03b))
RoIC = 15.65% (NOPAT 1.32b / Invested Capital 8.46b)
WACC = 6.72% (E(13.0b)/V(16.5b) * Re(6.53%) + D(3.54b)/V(16.5b) * Rd(9.30%) * (1-Tc(0.20)))
Discount Rate = 6.53% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -22.47 | Cagr: -26.39%
[DCF] Terminal Value 77.97% ; FCFF base≈1.02b ; Y1≈1.17b ; Y5≈1.72b
[DCF] Fair Price = 53.81 (EV 25.9b - Net Debt 2.99b = Equity 22.9b / Shares 425.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -9.43 | EPS CAGR: -6.13% | SUE: 0.0 | # QB: 0
Revenue Correlation: 85.76 | Revenue CAGR: 13.97% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=1.94 | Chg30d=-5.17% | Revisions=+20% | GrowthEPS=-4.7% | GrowthRev=+6.7%
EPS next Year (2027-12-31): EPS=2.18 | Chg30d=+4.28% | Revisions=+0% | GrowthEPS=+12.1% | GrowthRev=+5.6%
[Analyst] Revisions Ratio: +20%